Category: Science


Improving the Lives of Melanoma Survivors

By Cody R. Barnett, MRA Director of Communications | 15 October 2018 In Prevention, Science

Melanoma survivors are at a 9-fold increased risk of developing another melanoma. Unfortunately, 20% of survivors reported a sunburn in the past year and 10% intentionally went outside for a tan – both strong predictors of inappropriate sun exposure.

Read More


Older Patients Do Better on Immunotherapy

By Cody R. Barnett, MRA Director of Communications | 8 October 2018 In Science, Treatment

In Dr. Weeraratna's study, older patients did better on immunotherapy than younger patients. This surprising result is the opposite of what was expected.

Read More


Using Zebrafish to Shed New Light on Melanoma

By Cody R. Barnett, MRA Director of Communications | 29 August 2018 In Science

Dr. Liz Patton, a MRA-funded cancer researcher at the Medical Research Council Human Genetics Unit at the University of Edinburgh, is fascinated by learning how things work. Patton has focused her research on better understanding how melanocytes – the cells in our skin that provide us our coloring – develop, divide, migrate, and in some unfortunate circumstances, proliferate uncontrollably turning into melanoma. Her work is providing critical insight into the origin of melanoma and what spurs melanoma to spread throughout the body.

Read More


Maintaining the Pace of Melanoma Innovation in the Era of an Evolving Standard of Care

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 10 August 2018 In Science, Treatment

There is no doubt that treatments for metastatic melanoma have changed dramatically in the decade since MRA’s founding in 2007. How do we keep up the momentum?

Read More


Uveal ‘Clusters’ in Auburn, AL and Huntersville, NC

By Cody R. Barnett, MRA Director of Communications | 18 July 2018 In Allies & Partnerships, Melanoma Stories, News, Science, Treatment

When we talk about melanoma, it’s easy to forget that cutaneous – the most common variety that forms on the skin – isn’t the only game in town. Uveal represents about 5% of all melanomas diagnosed each year. So, when dozens of people from two towns in North Carolina and Alabama were diagnosed with the rare cancer alarm bells sounded.

Read More


Applying AI to Melanoma Detection

5 July 2018 In Prevention, Science

Is AI the future of detecting melanoma early, when it is easiest to cure?

Read More


Making the Most Out of Immunotherapy

11 June 2018 In Science, Treatment

Learn what MRA-funded investigators are doing to optimize immunotherapy for patients.

Read More


We’ve Teamed Up with the American Cancer Society

By Cody R. Barnett, MRA Director of Communications | 7 June 2018 In Allies & Partnerships, Science, Treatment

American Cancer Society and Melanoma Research Alliance have united to fund lifesaving research aimed at reducing side effects and improving outcomes for patients treated with immunotherapy.

Read More


American Cancer Society and Melanoma Research Alliance Fund Five Innovative Approaches to Reduce Immunotherapy Side Effects

10 May 2018 In Allies & Partnerships, Science

As the world marks Melanoma Awareness Month, the American Cancer Society (ACS) and the Melanoma Research Alliance (MRA) selected the first group of scientists to receive newly established research grants to investigate how to reduce rare, but serious, side effects resulting from cancer treatments with checkpoint inhibitors, a type of immunotherapy.

Read More


Tackling Brain Metastases

30 April 2018 In Science, Treatment

Brain metastases (mets) are a frequent and often deadly problem in patients with advanced melanoma. Nearly 40% of patients with metastatic melanoma have brain mets at diagnosis, with an average survival of only 4 months, suggesting a crucial need for treatments that can rid the brain of these tumors1,2. But new cancer treatments are rarely tested in patients with active brain mets. This is largely due to concerns about whether these patients will have side effects unique to brain mets, and poorer outcomes that may negatively weigh against otherwise positive clinical benefits. Another potential concern is whether the drugs will even penetrate the brain, which has a fortress-like ability to keep substances from entering it.

Read More


Login

×